Organization | Gesellschaft fur Padiatrische Onkologie und Hamatologie - Austria

Gesellschaft fur Padiatrische Onkologie und Hamatologie - Austria Report issue

Academic/Hospital Phase 3

Organization Overview

First Clinical Trial

2001

NCT00020566

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2009

Timeline

NOW

Now

Active Ingredients

Drugs in Phase 3 Trials (10)

autologous hematopoietic stem cells (1 trial)

busulfan (Myleran) (1 trial)

cyclophosphamide (cytoxan) (1 trial)

dactinomycin (cosmegen) (1 trial)

doxorubicin (Doxil) (1 trial)

etoposide (vepesid) (2 trials)

idarubicin (idamycin) (1 trial)

ifosfamide (ifex) (1 trial)

melphalan (alkeran) (1 trial)

vincristine (oncovin) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Rhabdomyosarcoma (Phase 3)

Sarcoma (Phase 3)

Overview

Highest Phase: Phase 3
# of Trials: 2
# of Trial APIs: 10